Larotrectinib wiki. and Bayer) for adult and pediatric patients with solid tumors El larotrectini...
Larotrectinib wiki. and Bayer) for adult and pediatric patients with solid tumors El larotrectinib, que se vende bajo la marca Vitrakvi, es un medicamento utilizado para tratar el cáncer. Larotrectinib, sold under the brand name Vitrakvi, is a medication for the treatment of cancer. Call your doctor at once if you have: severe or ongoing stomach pain, vomiting, or diarrhea; confusion, memory problems, severe dizziness; problems with speech or coordination Nov 29, 2018 · Larotrectinib is an orally administered inhibitor of tropomyosin receptor kinase (Trk), a receptor tyrosine kinase activated by neurotrophins which is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival. D'autres effets secondaires peuvent inclure des engourdissements, des tremblements ou un délire 2. Les effets secondaires du larotrectinib comprennent des problèmes de foie, un faible nombre de globules rouges, des douleurs musculaires, de la fatigue, un faible nombre de globules blancs, de la diarrhée, des nausées ou de la fièvre 3. There are several different tyrosine kinases. Larotrectinib (Vitrakvi) Larotrectinib is a type of targeted cancer drug. [4] Repotrectinib is an inhibitor of proto-oncogene tyrosine-protein kinase ROS1 (ROS1) and of the tropomyosin receptor tyrosine kinases (TRKs) TRKA, TRKB, and TRKC. It works by interfering with the growth of cancer cells, which are eventually destroyed. [4] The most common adverse reactions include dizziness, dysgeusia Larotrectinib (Vitrakvi®) belongs to a group of targeted therapy drugs called cancer growth inhibitors. The cancer will be tested for the gene change before you start Learn about VITRAKVI® (larotrectinib), a treatment for NTRK gene fusion positive solid tumors. Dec 29, 2025 · Larotrectinib side effects Get emergency medical help if you have signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat. Call your doctor at once if you have: severe or ongoing stomach pain, vomiting, or diarrhea; confusion, memory problems, severe dizziness; problems with speech or coordination Larotrectinib was the first drug to be specifically developed and approved to treat any cancer containing certain mutations, as opposed to cancers of specific tissues (i. Blocking these signals helps to slow or stop the cancer from growing. ChemSpider record containing structure, synonyms, properties, vendors and database links for Larotrectinib, 1223403-58-4, 20255616, NYNZQNWKBKUAII-KBXCAEBGSA-N Repotrectinib, sold under the brand name Augtyro, is an anti-cancer medication used for the treatment of non-small cell lung cancer. [4][7] It is taken by mouth. [8][9][10] It was discovered by Array BioPharma and licensed to Loxo Oncology in 2013. 8 Upon administration, larotrectinib binds to Trk, thereby preventing neurotrophin-Trk Larotrectinib was the first drug to be specifically developed and approved to treat any cancer containing certain mutations, as opposed to cancers of specific tissues (i. Larotrectinib may cause serious side effects. , the approval is " tissue agnostic "). [1][5][7] It is an inhibitor of tropomyosin kinase receptors TrkA, TrkB, and TrkC. You have tests on your cancer cells bef Larotrectinib is defined as an orally administered, first-generation ATP-competitive tyrosine kinase inhibitor (TKI) that effectively targets NTRK fusion-positive tumors across various cancers, including pediatric sarcomas, with demonstrated efficacy and a high safety profile. 3 Los efectos secundarios de este medicamento incluyen problemas hepáticos, niveles bajos de glóbulos rojos, dolor muscular, cansancio Larotrectinib Arzneimittelgruppen Kinasehemmer TRK-Inhibitoren Larotrectinib ist ein Wirkstoff aus der Gruppe der Kinasehemmer für die Behandlung von Patienten mit soliden Tumoren mit einer neurotrophen Tyrosin-Rezeptor-Kinase-Genfusion. Larotrectinib: learn about side effects, dosage, special precautions, and more on MedlinePlus. On November 26, 2018, the Food and Drug Administration granted accelerated approval to larotrectinib (VITRAKVI, Loxo Oncology Inc. It is a treatment for some cancers that have a change to the neurotrophic tyrosine receptor kinase (NTRK) gene. Larotrectinib is a type of targeted drug called a tyrosine kinase inhibitor (TKI) . Larotrectinib is used to treat cancers that have a genetic change in the cells called NTRK and cannot be treated with surgery. Die Effekte beruhen auf der selektiven und kompetitiven Hemmung der Tropomyosin-Rezeptor-Kinasen. Tyrosine kinases are proteins that cells use to signal to each other to grow. It is also called Vitrakvi. 1 2 Específicamente se utiliza para casos que tienen una fusión del gen del receptor tirosina quinasa neurotrófico, 2 y se toma por vía oral. They act as chemical messengers. e. Medscape - Solid tumors with NTRK gene fusion dosing for Vitrakvi (larotrectinib), frequency-based adverse effects, comprehensive interactions, contraindications, pregnancy & lactation schedules, and cost information. Feb 1, 2026 · Larotrectinib belongs to the group of medicines called antineoplastics (cancer medicines). Visit the official patient site to see safety and full prescribing information. kywburbqwzpwqbhgtlliiintbbquplftwqjxcxurxbqiznxfjpch